85 related articles for article (PubMed ID: 109199)
1. Histologic grade in advanced ovarian cancer.
Ozols RF; Garvin AJ; Costa J; Simon RM; Young RC
Cancer Treat Rep; 1979 Feb; 63(2):255-63. PubMed ID: 109199
[TBL] [Abstract][Full Text] [Related]
2. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
3. Combination v. sequential therapy with melphalan, 5-fluorouracil and methotrexate for advanced ovarian cancer.
Miller AB; Klaassen DJ; Boyes DA; Dodds DJ; Gerulath A; Kirk ME; Levitt M; Pearson JG; Wall C
Can Med Assoc J; 1980 Sep; 123(5):365-71. PubMed ID: 7020903
[TBL] [Abstract][Full Text] [Related]
4. Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy.
Young RC; Chabner BA; Hubbard SP; Fisher RI; Bender RA; Anderson T; Simon RM; Canellos GP; DeVita VT
N Engl J Med; 1978 Dec; 299(23):1261-6. PubMed ID: 101843
[TBL] [Abstract][Full Text] [Related]
5. Advanced ovarian cancer: correlation of histologic grade with response to therapy and survival.
Ozols RF; Garvin AJ; Costa J; Simon RM; Young RC
Cancer; 1980 Feb; 45(3):572-81. PubMed ID: 7353206
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
Thigpen T; Vance R; Puneky L; Khansur T
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of advanced ovarian cancer].
de Gramont A; Krulik M; Pigne A; Brissaud P; Sirinelli A; Hubert D; Zylberait D; Debray J
Sem Hop; 1984 Mar; 60(14):957-60. PubMed ID: 6326283
[TBL] [Abstract][Full Text] [Related]
9. [Advanced epithelial cancers of the ovary: results of 4 chemotherapy protocols (110 cases)].
Israël L; Lepage E; Breau JL; Aguilera J
Bull Cancer; 1982; 69(5):426-33. PubMed ID: 6891902
[TBL] [Abstract][Full Text] [Related]
10. Treatment of advanced ovarian carcinoma with a combination of hexmethylmelamine, cyclophosphamide, methotrexate, and 5-fluorourcil (hexa-CAF) in patients with and without previous treatment.
Neijt JP; van Lindert AC; Vendrik CP; Roozendaal KJ; Struyvenberg A; Pinedo HM
Cancer Treat Rep; 1980; 64(2-3):323-6. PubMed ID: 6773656
[TBL] [Abstract][Full Text] [Related]
11. Hexa-CAF combination chemotherapy and other multiple-drug regimens in advanced ovarian carcinoma: present and future.
Neijt JP; van Lindert AC; Vendrik CP; Roozendaal KJ; Struyvenberg A; Pinedo HM
Neth J Med; 1979; 22(2):38-44. PubMed ID: 107464
[No Abstract] [Full Text] [Related]
12. Combination chemotherapy for advanced ovarian cancer: a prospective randomized trial comparing hexamethylmelamine and cyclophosphamide to doxorubicin and cyclophosphamide.
Schwartz PE; Lawrence R; Katz M
Cancer Treat Rep; 1981; 65(1-2):137-41. PubMed ID: 6261948
[TBL] [Abstract][Full Text] [Related]
13. Controlled prospective trial of combination chemotherapy with cyclophosphamide, adriamycin, and 5-fluorouracil for the treatment of advanced ovarian cancer: a preliminary report.
Bruckner HW; Pagano M; Falkson G; Creech R; Arseneau JC; Horton J; Brodovsky H; Davis TE; Slayton RW; Greenspan E
Cancer Treat Rep; 1979 Feb; 63(2):297-9. PubMed ID: 376136
[No Abstract] [Full Text] [Related]
14. Preliminary report of a clinical trial of the treatment of patients with advanced stage III and IV ovarian cancer with melphalan, 5-fluorouracil, and methotrexate in combination and sequentially: a study of the Clinical Trials Group of the National Cancer Institute of Canada.
Klaassen DJ; Boyes DA; Gerulath A; Levitt M; Miller AB; Pearson JG
Cancer Treat Rep; 1979 Feb; 63(2):289-95. PubMed ID: 376135
[No Abstract] [Full Text] [Related]
15. Second-line chemotherapy of stage III-IV ovarian carcinoma: a randomized comparison of melphalan to melphalan and hexamethylmelamine in patients with persistent disease after doxorubicin and cisplatin.
Pater JL; Carmichael JA; Krepart GV; Fraser RC; Roy M; Kirk ME; Levitt M; Brown LB; Wilson KS; Shelley WE
Cancer Treat Rep; 1987 Mar; 71(3):277-81. PubMed ID: 3102056
[TBL] [Abstract][Full Text] [Related]
16. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801
[TBL] [Abstract][Full Text] [Related]
17. Single agent vs combination chemotherapy in the treatment of ovarian cancer.
Barlow JJ; Piver MS
Obstet Gynecol; 1977 May; 49(5):609-11. PubMed ID: 850579
[TBL] [Abstract][Full Text] [Related]
18. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
19. Toward the development of a universal grading system for ovarian epithelial carcinoma. I. Prognostic significance of histopathologic features--problems involved in the architectural grading system.
Shimizu Y; Kamoi S; Amada S; Hasumi K; Akiyama F; Silverberg SG
Gynecol Oncol; 1998 Jul; 70(1):2-12. PubMed ID: 9698465
[TBL] [Abstract][Full Text] [Related]
20. The importance of the histologic grade of invasive breast carcinoma and response to chemotherapy.
Pinder SE; Murray S; Ellis IO; Trihia H; Elston CW; Gelber RD; Goldhirsch A; Lindtner J; Cortés-Funes H; Simoncini E; Byrne MJ; Golouh R; Rudenstam CM; Castiglione-Gertsch M; Gusterson BA
Cancer; 1998 Oct; 83(8):1529-39. PubMed ID: 9781946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]